A Pilot Study of Immune Checkpoint Inhibition (Durvalumab With or Without Tremelimumab) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Next Previous
Trial Profile

A Pilot Study of Immune Checkpoint Inhibition (Durvalumab With or Without Tremelimumab) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab
  • Indications Pancreatic cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 09 Mar 2018 Protocol was amended as Phase 2 has been added and factorial assignment has been changed to sequential assignment.
    • 09 Mar 2018 Planned End Date changed from 30 Apr 2018 to 31 Dec 2019.
    • 09 Mar 2018 Planned primary completion date changed from 30 Apr 2018 to 31 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top